Results 191 to 200 of about 6,125,000 (281)

Investigating the cell of origin and novel molecular targets in Merkel cell carcinoma: a historic misnomer

Molecular Oncology, EarlyView.
This study indicates that Merkel cell carcinoma (MCC) does not originate from Merkel cells, and identifies gene, protein & cellular expression of immune‐linked and neuroendocrine markers in primary and metastatic Merkel cell carcinoma (MCC) tumor samples, linked to Merkel cell polyomavirus (MCPyV) status, with enrichment of B‐cell and other immune cell
Richie Jeremian, Sriraam Sivachandran, Melissa Galati, Brandon Ramchatesingh, Hibo Rijal, Johnny Hanna, Elena Netchiporouk, May Chergui, Margaret Redpath, Samy Abou Setah, Ivan V. Litvinov   +10 more
wiley   +1 more source

Exploring the prognosis of rictor(+) in high-risk population: lasso regression for enhancing overall survival in primary gastric adenocarcinoma. [PDF]

World J Surg Oncol
Cheng W, Chang Y, Ma J, Li Y, Hu R.
europepmc   +1 more source

Identification and validation of prognostic signature genes of bladder cancer by integrating methylation and transcriptomic analysis [PDF]

Dipankor Chatterjee, Sadia Islam Mou, Tamanna Sultana, Md. Ismail Hosen, Md. Omar Faruk   +4 more
openalex   +1 more source

Validation of a scale of measurement of service quality, image, customer satisfaction and loyalty in traditional trade [PDF]

, 2019
Cláudia Miranda Veloso, Ana Paula Monte
openalex   +1 more source

Validation framework for epidemiological models with application to COVID-19 models

, 2023
Kimberly A. Dautel, Ephraim Agyingi, Pras Pathmanathan   +2 more
openalex   +2 more sources

The influence of ROS1 fusion partners and resistance mechanisms in ROS1‐TKI‐treated non‐small cell lung cancer patients

Molecular Oncology, EarlyView.
This real‐world study of ROS1+ NSCLC highlights fusion diversity, treatment outcomes with crizotinib and lorlatinib, and in vitro experiments with resistance mechanisms. G2032R drives strong resistance to ROS1‐targeted TKIs, especially lorlatinib. Fusion partner location does not affect overall survival to crizotinib or lorlatinib. Findings support the
Fenneke Zwierenga, Christa Dijkhuizen, Patrick Korthuis, Wim Timens, Harry Groen, Jeroen Hiltermann, Anke van den Berg, Lyndsay Drayer, Anthonie van der Wekken   +8 more
wiley   +1 more source

A global land daily 10-km-resolution surface ozone dataset from 2013-2022. [PDF]

Sci Data
Wang R, Shen H, Zeng C, Chen J, Wang Y, Li Y.   +5 more
europepmc   +1 more source

Emerging role of ARHGAP29 in melanoma cell phenotype switching

Molecular Oncology, EarlyView.
This study gives first insights into the role of ARHGAP29 in malignant melanoma. ARHGAP29 was revealed to be connected to tumor cell plasticity, promoting a mesenchymal‐like, invasive phenotype and driving tumor progression. Further, it modulates cell spreading by influencing RhoA/ROCK signaling and affects SMAD2 activity. Rho GTPase‐activating protein
Beatrice Charlotte Tröster, Melanie Kappelmann‐Fenzl, Anja Katrin Bosserhoff, Nicole Rachinger   +3 more
wiley   +1 more source

Construction and validation of a multi-dimensional health indicator-driven osteoporosis risk prediction model: a large-sample cross-sectional study based on two centers. [PDF]

BMC Musculoskelet Disord
Cai Z, Lu X, Ni H, Xu Z.
europepmc   +1 more source

Major bioactive phenolics in Bergenia species from the Indian Himalayan region: Method development, validation and quantitative estimation using UHPLC-QqQLIT-MS/MS

, 2017
Renu Pandey, Brijesh Kumar, Baleshwar Meena, Mukesh Srivastava, Tripti Mishra, Vandana Tiwari, Mahesh Pal, Narayanan K. Nair, D. K. Upreti, Tikam Singh Rana   +9 more
openalex   +2 more sources